Xue-Yan Cui

  • Senior Researcher; MD, PhD
  • +47 23 07 21 84
 

Publications 2022

Cui XY, Stavik B, Thiede B, Sandset PM, Kanse SM (2022)
FSAP Protects against Histone-Mediated Increase in Endothelial Permeability In Vitro
Int J Mol Sci, 23 (22)
DOI 10.3390/ijms232213706, PubMed 36430180

Garabet L, Eriksson A, Tjønnfjord E, Cui XY, Olsen MK, Jacobsen HK, Jørgensen CT, Mathisen ÅB, Mowinckel MC, Ahlen MT, Sørvoll IH, Horvei KD, Ernstsen SL, Lægreid IJ, Stavik B, Holst R, Sandset PM, Ghanima W (2022)
SARS-CoV-2 vaccines are not associated with hypercoagulability in apparently healthy people
Res Pract Thromb Haemost, 100002 (in press)
DOI 10.1016/j.rpth.2022.100002, PubMed 36448024

Publications 2021

Cui XY, Tjønnfjord GE, Kanse SM, Dahm AEA, Iversen N, Myklebust CF, Sun L, Jiang ZX, Ueland T, Campbell JJ, Ho M, Sandset PM (2021)
Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia
Sci Rep, 11 (1), 5127
DOI 10.1038/s41598-021-84695-8, PubMed 33664415

Publications 2017

Cui XY, Skretting G, Tinholt M, Stavik B, Dahm AEA, Sahlberg KK, Kanse S, Iversen N, Sandset PM (2017)
A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7
Thromb Res, 157, 111-116
DOI 10.1016/j.thromres.2017.07.013, PubMed 28734156

Publications 2016

Stavik B, Espada S, Cui XY, Iversen N, Holm S, Mowinkel MC, Halvorsen B, Skretting G, Sandset PM (2016)
EPAS1/HIF-2 alpha-mediated downregulation of tissue factor pathway inhibitor leads to a pro-thrombotic potential in endothelial cells
Biochim Biophys Acta, 1862 (4), 670-678
DOI 10.1016/j.bbadis.2016.01.017, PubMed 26826018

Publications 2013

Cui XY, Skretting G, Jing Y, Sun H, Sandset PM, Sun L (2013)
Hypoxia influences stem cell-like properties in multidrug resistant K562 leukemic cells
Blood Cells Mol Dis, 51 (3), 177-84
DOI 10.1016/j.bcmd.2013.05.003, PubMed 23725749

Page visits: 4933